Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Alzheimer’s drug aducanumab, which the U.S. biotech company had declared a failure earlier this year. The turnabout has raised concern that the company is being more optimistic than its trial results warrant as it makes a case for a desperately needed treatment that, if approved, could be the first to slow progression of the mind-wasting disease. For Biogen, the financial prospects are enormous. …read more
Source:: Yahoo Finance
